David Katzenstein

21.0k total citations · 6 hit papers
281 papers, 15.2k citations indexed

About

David Katzenstein is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, David Katzenstein has authored 281 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 229 papers in Infectious Diseases, 203 papers in Virology and 79 papers in Epidemiology. Recurrent topics in David Katzenstein's work include HIV Research and Treatment (203 papers), HIV/AIDS Research and Interventions (181 papers) and HIV/AIDS drug development and treatment (166 papers). David Katzenstein is often cited by papers focused on HIV Research and Treatment (203 papers), HIV/AIDS Research and Interventions (181 papers) and HIV/AIDS drug development and treatment (166 papers). David Katzenstein collaborates with scholars based in United States, Zimbabwe and South Africa. David Katzenstein's co-authors include Scott M. Hammer, Martin Hirsch, Robert T. Schooley, Margaret A. Fischl, Michael S. Saag, Douglas D. Richman, Patrick Yéni, Donna M. Jacobsen, Stefano Vella and Melanie Thompson and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David Katzenstein

281 papers receiving 14.6k citations

Hit Papers

Antiretroviral Therapy in Adults 1996 2026 2006 2016 2000 1998 1996 2006 2004 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antiretroviral Therapy in Adults
    2000 874 citations Margaret A. Fischl, Scott M. Hammer et al. profile →
  2. Antiretroviral Therapy for HIV Infection in 1998
    1998 837 citations Margaret A. Fischl, Scott M. Hammer et al. profile →
  3. A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter
    1996 768 citations Scott M. Hammer, David Katzenstein et al. profile →
  4. Treatment for Adult HIV Infection
    2006 767 citations Scott M. Hammer, Michael S. Saag et al. profile →
  5. Treatment for Adult HIV Infection
    2004 601 citations Scott M. Hammer, Michael S. Saag et al. profile →
  6. Antiretroviral Treatment for Adult HIV Infection in 2002
    2002 573 citations Scott M. Hammer, Margaret A. Fischl et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Katzenstein United States 60 11.5k 9.5k 3.6k 1.7k 924 281 15.2k
Pietro Vernazza Switzerland 64 9.7k 0.8× 6.4k 0.7× 4.4k 1.2× 1.9k 1.1× 1.3k 1.4× 222 12.9k
Ann C. Collier United States 65 9.1k 0.8× 9.1k 1.0× 3.3k 0.9× 3.0k 1.7× 481 0.5× 256 14.9k
Robert W. Coombs United States 59 11.8k 1.0× 8.9k 0.9× 5.7k 1.6× 1.8k 1.1× 1.8k 2.0× 235 16.8k
Bernard Hirschel Switzerland 71 11.4k 1.0× 8.8k 0.9× 5.4k 1.5× 3.6k 2.1× 494 0.5× 337 17.5k
Stefano Vella Italy 53 10.4k 0.9× 8.2k 0.9× 3.5k 1.0× 2.2k 1.3× 491 0.5× 247 13.6k
Susan A. Fiscus United States 56 7.8k 0.7× 6.5k 0.7× 2.8k 0.8× 997 0.6× 1.0k 1.1× 195 10.0k
Joep M. A. Lange Netherlands 62 9.2k 0.8× 9.3k 1.0× 3.3k 0.9× 2.0k 1.2× 490 0.5× 293 14.2k
M. John Gill Canada 53 6.5k 0.6× 4.2k 0.4× 3.9k 1.1× 2.2k 1.3× 635 0.7× 395 11.3k
Eric S. Daar United States 55 7.3k 0.6× 7.2k 0.8× 2.9k 0.8× 2.5k 1.5× 503 0.5× 239 11.5k
Scott M. Hammer United States 52 12.3k 1.1× 10.2k 1.1× 3.9k 1.1× 2.3k 1.3× 408 0.4× 129 16.0k

Countries citing papers authored by David Katzenstein

Since Specialization
Citations

This map shows the geographic impact of David Katzenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Katzenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Katzenstein more than expected).

Fields of papers citing papers by David Katzenstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Katzenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Katzenstein. The network helps show where David Katzenstein may publish in the future.

Co-authorship network of co-authors of David Katzenstein

This figure shows the co-authorship network connecting the top 25 collaborators of David Katzenstein. A scholar is included among the top collaborators of David Katzenstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Katzenstein. David Katzenstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Machekano, Rhoderick, Shungu Munyati, Junior Mutsvangwa, et al.. (2022). Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale. AIDS Research and Human Retroviruses. 38(10). 774–778. 5 indexed citations
2.
3.
Shamu, Tinei, Tom Wilsgaard, Tsitsi Bandason, et al.. (2018). Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe. International Journal of Infectious Diseases. 78. 65–71. 12 indexed citations
4.
Chimukangara, Benjamin, et al.. (2017). Community Based Antiretroviral Treatment in Rural Zimbabwe. AIDS Research and Human Retroviruses. 33(12). 1185–1191. 8 indexed citations
5.
Manasa, Justen, et al.. (2012). Primary Drug Resistance in South Africa: Data from 10 Years of Surveys. AIDS Research and Human Retroviruses. 28(6). 558–565. 47 indexed citations
6.
Kassaye, Seble, Esther Lee, Rami Kantor, et al.. (2007). Drug Resistance in Plasma and Breast Milk after Single-Dose Nevirapine in Subtype C HIV Type 1: Population and Clonal Sequence Analysis. AIDS Research and Human Retroviruses. 23(8). 1055–1061. 27 indexed citations
7.
Balakrishnan, Pachamuthu, Nagalingeswaran Kumarasamy, Rami Kantor, et al.. (2005). HIV Type 1 Genotypic Variation in an Antiretroviral Treatment-Naive Population in Southern India. AIDS Research and Human Retroviruses. 21(4). 301–305. 55 indexed citations
8.
Kantor, Rami, David Katzenstein, Matthew J. Gonzales, et al.. (2002). Influence of subtype and treatment on genetic profiles of HIV-1 reverse transcriptase and protease: do they act independently in predicting position-specific mutation probabilities in non-subtype B sequences?. Antiviral Therapy. 7. 1 indexed citations
9.
Kantor, Rami, Lynn S. Zijenah, Robert W. Shafer, et al.. (2002). HIV-1 Subtype C Reverse Transcriptase and Protease Genotypes in Zimbabwean Patients Failing Antiretroviral Therapy. AIDS Research and Human Retroviruses. 18(18). 1407–1413. 50 indexed citations
10.
Katzenstein, David, Michael D. Hughes, Mary Albrecht, et al.. (2001). Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection. AIDS Research and Human Retroviruses. 17(3). 203–210. 2 indexed citations
11.
Tien, Phyllis C., Robert W. Shafer, Christopher H. Contag, David Katzenstein, & Maneesh Batra. (2000). HIV Type 1 Envelope Subtype C Sequences from Recent Seroconverters in Zimbabwe. AIDS Research and Human Retroviruses. 16(10). 973–979. 30 indexed citations
12.
Katzenstein, David, H. Hughes, Mary Albrecht, et al.. (2000). Virologic and CD4 + Cell Responses to New Nucleoside Regimens: Switching to Stavudine or Adding Lamivudine after Prolonged Zidovudine Treatment of Human Immunodeficiency Virus Infection. AIDS Research and Human Retroviruses. 16(11). 1031–1037. 11 indexed citations
13.
Albrecht, Mary, Michael D. Hughes, Shu-Hao Liou, et al.. (2000). Effect of Lamivudine in HIV-Infected Persons with Prior Exposure to Zidovudine/Didanosine or Zidovudine/Zalcitabine. AIDS Research and Human Retroviruses. 16(14). 1337–1344. 2 indexed citations
14.
Marschner, Ian C., Ann C. Collier, Robert W. Coombs, et al.. (1998). Use of Changes in Plasma Levels of Human Immunodeficiency Virus Type 1 RNA to Assess the Clinical Benefit of Antiretroviral Therapy. The Journal of Infectious Diseases. 177(1). 40–47. 182 indexed citations
15.
Holodniy, Mark, David Katzenstein, Dennis Israelski, & T. C. Merigan. (1991). Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.. Journal of Clinical Investigation. 88(5). 1755–1759. 68 indexed citations
16.
Holodniy, Mark, et al.. (1991). Detection and Quantification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction. The Journal of Infectious Diseases. 163(4). 862–866. 133 indexed citations
17.
Vujcic, Luba K., et al.. (1990). International Collaborative Study to Compare Assays for Antibodies that Neutralize Human Immunodeficiency Virus. AIDS Research and Human Retroviruses. 6(7). 847–853. 13 indexed citations
18.
Sawyer, Leigh A., David Katzenstein, R. Michael Hendry, et al.. (1990). Possible Beneficial Effects of Neutralizing Antibodies and Antibody-Dependent, Cell-Mediated Cytotoxicity in Human Immunodeficiency Virus Infection. AIDS Research and Human Retroviruses. 6(3). 341–356. 66 indexed citations
19.
Katzenstein, David, et al.. (1986). Successful treatment of murine cytomegalovirus disease does not prevent latent virus infection.. Journal of Laboratory and Clinical Medicine. 108(2). 155–160. 7 indexed citations
20.
Katzenstein, David, et al.. (1978). Role of blocking antibody in disseminated gonococcal infection.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 121(5). 1884–8. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pietro Vernazza Breakdown of academic impact, for papers by Ann C. Collier Breakdown of academic impact, for papers by Robert W. Coombs Breakdown of academic impact, for papers by Bernard Hirschel Breakdown of academic impact, for papers by Stefano Vella Breakdown of academic impact, for papers by Susan A. Fiscus Breakdown of academic impact, for papers by Joep M. A. Lange Breakdown of academic impact, for papers by M. John Gill Breakdown of academic impact, for papers by Eric S. Daar Breakdown of academic impact, for papers by Scott M. Hammer
Rankless by CCL
2026